First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.7086
Abstract: Importance Recently, new drugs have been approved for the first-line treatment of metastatic renal cell carcinoma (mRCC). Nivolumab plus ipilimumab significantly increases overall survival for intermediate- and poor-risk patients with mRCC. However, considering the high… read more here.
Keywords: first line; sunitinib; nivolumab plus; plus ipilimumab ... See more keywords
Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4743
Abstract: Sunitinib is one of the first‐line targeted drugs for metastatic renal cell carcinoma (RCC) with dual effects of antiangiogensis and proapoptosis. Sam68 (Src‐associated in mitosis, 68 KDa), is found being involved in cell apoptosis. This… read more here.
Keywords: sam68 expression; cell; apoptosis; sunitinib ... See more keywords
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5483
Abstract: The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untreated advanced renal cell carcinoma. This subset analysis investigated… read more here.
Keywords: sunitinib; plus pembrolizumab; pembrolizumab versus; lenvatinib plus ... See more keywords
Special issue “The advance of solid tumor research in China”: Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34294
Abstract: Clinically effective methods to predict the efficacy of sunitinib, for patients with metastatic or locally advanced pancreatic neuroendocrine tumors (panNET) are scarce, making precision treatment difficult. This study aimed to develop and validate a computed… read more here.
Keywords: sunitinib; efficacy; value; pancreatic neuroendocrine ... See more keywords
Sunitinib does not acutely alter left ventricular systolic function, but induces diastolic dysfunction
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3593-9
Abstract: PurposeCancer chemotherapies have improved the prognosis of cancer patients in recent years; however, their side effects on the cardiovascular systems have emerged as a major concern in the field of both cardiology and oncology. In… read more here.
Keywords: cardiovascular adverse; sunitinib; cardiac troponin; adverse events ... See more keywords
Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-022-04432-4
Abstract: Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). High variability in pharmacokinetics coupled with a proven exposure–effect relationship makes sunitinib an ideal candidate for therapeutic drug… read more here.
Keywords: feasibility; response; renal cell; toxicity ... See more keywords
Posterior reversible encephalopathy syndrome after long-term treatment with low-dose sunitinib: a case report
Sign Up to like & getrecommendations! Published in 2017 at "Neurological Sciences"
DOI: 10.1007/s10072-017-2851-7
Abstract: Posterior reversible encephalopathy syndrome (PRES) is an acute neurological disorder characterized by headache, visual disturbances, seizures and vigilance status alteration. Brain magnetic resonance imaging (MRI) reveals subcortical vasogenic edema usually affecting the posterior circulation territories… read more here.
Keywords: encephalopathy syndrome; sunitinib; posterior reversible; case ... See more keywords
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
Sign Up to like & getrecommendations! Published in 2021 at "Targeted Oncology"
DOI: 10.1007/s11523-020-00784-0
Abstract: Background Sunitinib prolonged progression-free survival (PFS) versus placebo in patients with metastatic pancreatic neuroendocrine tumors (panNETs) in a phase III trial. The efficacy and safety of sunitinib in patients with panNETs were confirmed in an… read more here.
Keywords: phase; trial; pancreatic neuroendocrine; combined cohort ... See more keywords
Protective Effect of RIVA Against Sunitinib-Induced Cardiotoxicity by Inhibiting Oxidative Stress-Mediated Inflammation: Probable Role of TGF-β and Smad Signaling
Sign Up to like & getrecommendations! Published in 2019 at "Cardiovascular Toxicology"
DOI: 10.1007/s12012-019-09551-8
Abstract: Sunitinib (SUN) is an oral tyrosine kinase inhibitor approved in 2006 as a first-line treatment for metastatic renal cell cancer. However, weak selectivity to kinase receptors and cardiotoxicity have limited the use of sunitinib. Rivaroxaban… read more here.
Keywords: induced cardiotoxicity; treatment; sunitinib induced; sunitinib ... See more keywords
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer letters"
DOI: 10.1016/j.canlet.2017.09.032
Abstract: The identification of new therapeutic strategies is urgently needed for the management of patients affected by anaplastic thyroid cancer (ATC) due to their short survival and poor prognosis. Aim of the study was to determine… read more here.
Keywords: combination; irinotecan sunitinib; anaplastic thyroid; sunitinib ... See more keywords
Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmaceutical and Biomedical Analysis"
DOI: 10.1016/j.jpba.2018.08.013
Abstract: HIGHLIGHTSSunitinib is a tyrosine kinase inhibitor and a candidate for TDM approach.Sunitinib and N‐desethyl sunitinib undergo light‐induced Z/E isomerization.Sample handling/analysis require light protection to preserve the active Z‐form.A fast and quantitative reconversion of the E‐… read more here.
Keywords: isomer; clinical routine; sunitinib; therapeutic drug ... See more keywords